Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing precisely aliskiren (as aliskiren fumarate) 150 milligram and hydrochlorothiazide 25 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Aliskiren (as aliskiren fumarate) 300 mg and hydrochlorothiazide 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Aliskiren (as aliskiren fumarate) 300 mg and hydrochlorothiazide 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely aliskiren (as aliskiren fumarate) 150 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely aliskiren (as aliskiren fumarate) 150 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely aliskiren (as aliskiren fumarate) 300 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely aliskiren (as aliskiren fumarate) 300 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely bisoprolol fumarate 5 milligram and hydrochlorothiazide 6.25 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely bisoprolol fumarate 5 milligram and hydrochlorothiazide 6.25 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Bisoprolol fumarate 2.5 mg and hydrochlorothiazide 6.25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Bisoprolol fumarate 2.5 mg and hydrochlorothiazide 6.25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely enalapril maleate 10 milligram and hydrochlorothiazide 25 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely enalapril maleate 10 milligram and hydrochlorothiazide 25 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Enalapril maleate 5 mg and hydrochlorothiazide 12.5 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Enalapril maleate 5 mg and hydrochlorothiazide 12.5 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Eprosartan (as eprosartan mesilate) 600 mg and hydrochlorothiazide 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Eprosartan (as eprosartan mesilate) 600 mg and hydrochlorothiazide 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely eprosartan (as eprosartan mesilate) 600 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely eprosartan (as eprosartan mesilate) 600 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely fosinopril sodium 10 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely fosinopril sodium 10 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely fosinopril sodium 20 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely fosinopril sodium 20 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amiloride hydrochloride 2.5 milligram and hydrochlorothiazide 25 milligram and timolol maleate 10 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely amiloride hydrochloride 2.5 milligram and hydrochlorothiazide 25 milligram and timolol maleate 10 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Captopril 25 mg and hydrochlorothiazide 12.5 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 12.5 milligram and lisinopril 20 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 12.5 milligram and lisinopril 20 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 12.5 milligram and losartan potassium 50 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Captopril 25 mg and hydrochlorothiazide 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydralazine hydrochloride 50 milligram and hydrochlorothiazide 50 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydralazine hydrochloride 50 milligram and hydrochlorothiazide 50 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 25 mg and labetalol hydrochloride 300 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Hydrochlorothiazide 25 mg and labetalol hydrochloride 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Hydrochlorothiazide 25 mg and lisinopril 20 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 25 mg and lisinopril 20 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 15 mg and methyldopa 250 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 25 mg and methyldopa 250 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 30 mg and methyldopa 500 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 30 mg and methyldopa 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 25 milligram and quinapril 20 milligram/1 each conventional release oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 25 milligram and quinapril 20 milligram/1 each conventional release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 12.5 mg and valsartan 80 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Benazepril hydrochloride 20 mg and hydrochlorothiazide 12.5 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Benazepril hydrochloride 20 mg and hydrochlorothiazide 12.5 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Candesartan cilexetil 32 mg and hydrochlorothiazide 12.5 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Candesartan cilexetil 32 mg and hydrochlorothiazide 12.5 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 12.5 mg and olmesartan medoxomil 20 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Hydrochlorothiazide 12.5 mg and olmesartan medoxomil 40 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Hydrochlorothiazide 25 mg and valsartan 160 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 25 mg and valsartan 160 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 25 mg and timolol maleate 10 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Hydrochlorothiazide 25 mg and timolol maleate 10 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Hydrochlorothiazide 12.5 mg and moexipril hydrochloride 7.5 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 12.5 mg and moexipril hydrochloride 7.5 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 12.5 mg and moexipril hydrochloride 15 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 12.5 mg and moexipril hydrochloride 15 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 25 milligram and metoprolol tartrate 100 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely hydrochlorothiazide 25 milligram and metoprolol tartrate 50 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely hydrochlorothiazide 25 milligram and metoprolol tartrate 50 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Hydrochlorothiazide 25 mg and valsartan 320 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 25 mg and valsartan 320 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 12.5 mg and valsartan 320 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 12.5 milligram and metoprolol tartrate 25 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely hydrochlorothiazide 12.5 milligram and metoprolol tartrate 50 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely hydrochlorothiazide 12.5 milligram and metoprolol tartrate 50 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely hydrochlorothiazide 25 milligram and metoprolol tartrate 200 milligram/1 each prolonged-release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely hydrochlorothiazide 25 milligram and metoprolol tartrate 200 milligram/1 each prolonged-release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Hydrochlorothiazide 25 mg and telmisartan 80 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 25 mg and telmisartan 80 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 25 milligram and quinapril (as quinapril hydrochloride) 20 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 25 milligram and quinapril (as quinapril hydrochloride) 20 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 12.5 milligram and quinapril (as quinapril hydrochloride) 20 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 12.5 milligram and quinapril (as quinapril hydrochloride) 20 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 12.5 milligram and nebivolol (as nebivolol hydrochloride) 5 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely hydrochlorothiazide 12.5 milligram and nebivolol (as nebivolol hydrochloride) 5 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing hydrochlorothiazide and nebivolol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Hydrochlorothiazide- and nebivolol-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing only hydrochlorothiazide and nebivolol in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Hydrochlorothiazide and nebivolol only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Hydrochlorothiazide and levamlodipine only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide- and levamlodipine-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide- and levamlodipine-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 12.5 mg and levamlodipine (as levamlodipine besilate) 2.5 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Hydrochlorothiazide 12.5 mg and levamlodipine (as levamlodipine besilate) 2.5 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing only hydrochlorothiazide and levamlodipine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely hydrochlorothiazide 12.5 milligram and irbesartan (as irbesartan hydrochloride) 150 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 12.5 milligram and irbesartan (as irbesartan hydrochloride) 150 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 12.5 milligram and irbesartan (as irbesartan hydrochloride) 300 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 12.5 milligram and irbesartan (as irbesartan hydrochloride) 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 25 milligram and irbesartan (as irbesartan hydrochloride) 300 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 25 milligram and irbesartan (as irbesartan hydrochloride) 300 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Candesartan cilexetil 8 mg and hydrochlorothiazide 12.5 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Candesartan cilexetil 8 mg and hydrochlorothiazide 12.5 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely hydrochlorothiazide 25 milligram and olmesartan medoxomil 20 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Hydrochlorothiazide (substance) |
Inferred relationship |
Some |
1 |